Drugs Made In America Acquisition Corp. (DMAAR) Long-Term Investments (2025 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Long-Term Investments for 2 consecutive years, with $146.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Investments fell 37.56% year-over-year to $146.8 million; the trailing twelve-month figure through Jun 2026 stood at $146.8 million (down 37.56% YoY), and the FY2025 full-year result was $239.9 million, changed N/A from the prior year.
• Long-Term Investments retreated to $146.8 million in Q2 2026 per DMAAR's latest filing, from $239.9 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $239.9 million in Q4 2025 and bottomed at $146.8 million in Q2 2026.